Corcept Therapeutics (CORT) Form 144 Filing Reports 2,200-Share Sale
Rhea-AI Filing Summary
Form 144 notice for Corcept Therapeutics, Inc. (CORT) discloses a proposed sale of 2,200 common shares to be executed on 09/10/2025 through Fidelity Brokerage Services (NASDAQ). The filing lists an aggregate market value of $159,390 and reports 105,371,729 shares outstanding. The shares were acquired under an option granted 08/20/2018 and the reported payment method is cash. The filer, identified in past sales as Daniel Swisher, sold three prior blocks of 2,200 shares each on 06/10/2025, 07/10/2025 and 08/11/2025, with gross proceeds shown for each sale. Remarks and signature attestations are present but no additional explanatory text or plan-adoption date is provided.
Positive
- Disclosure compliance: The filing reports proposed sales and recent sales consistent with Rule 144 requirements
- Transaction detail provided: Broker, number of shares, aggregate market value, acquisition source (option granted 08/20/2018) and payment method (cash) are all listed
Negative
- Insider selling activity: The filer executed three prior sales of 2,200 shares each within the past three months and proposes another sale, indicating ongoing dispositions
- Context missing: No date is provided for any Rule 10b5-1 trading plan or additional explanation for the sales, limiting investor understanding of whether trades follow a pre-established plan
Insights
TL;DR Routine insider sale filing showing option-derived shares and multiple recent small disposals by the same insider.
The filing is procedural and complies with Rule 144 disclosure by reporting a proposed sale of 2,200 common shares to occur on 09/10/2025 via a registered broker with an aggregate market value of $159,390. The shares were obtained from an option granted in 2018 and will be paid in cash. Historical sales by the same individual are documented for the prior three months, each for 2,200 shares with stated gross proceeds. There is no additional financial performance, forward guidance, or corporate action described. The filing provides the necessary sale/acquisition chronology but does not include any explanatory context such as reasons for the sales or a 10b5-1 plan adoption date.
TL;DR Disclosure meets form requirements but lacks contextual details on trading plan or material nonpublic information.
The notice documents an insider-originated transaction sequence and includes the standard attestation regarding material adverse information. It specifies acquisition via an option granted 08/20/2018 and a cash sale scheduled 09/10/2025, which suggests the sale arises from option exercise and subsequent disposition. The repeated small block sales over recent months are disclosed, enabling market transparency. The document does not state a plan adoption date for Rule 10b5-1 or additional remarks that would clarify whether sales follow a pre-existing trading plan.